Adeera D. Levin

Efficacy and safety of canagliflozin are consistent across polypharmacy burden in CKD: the CREDENCE trial.

Journal: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

Published: September 04, 2026

Does Intravenous Iron Improve Survival and Physical Function and Reduce Heart Failure Events in Patients with Chronic Kidney Disease?

Journal: NEJM evidence

Published: August 25, 2026

Reframing kidney outcomes in CKD trials: eGFR slopes, competing risks, and pragmatic trial design.

Journal: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

Published: August 17, 2026

Design and baseline characteristics of the ZENITH high proteinuria trial testing zibotentan/dapagliflozin efficacy in CKD.

Journal: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

Published: August 04, 2026

CV risk: if you aren't testing ACR, you aren't seeing the full picture.

Journal: Postgraduate medicine

Published: July 06, 2026

From Dialysis Expansion to Prevention-First Kidney Care: Lessons from Thailand's Response to CKD.

Journal: Kidney international reports

Published: June 29, 2026

Sex disparities in receiving evidence-based medications in patients with CKD.

Journal: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

Published: June 19, 2026

Authors reply: "Global kidney health: Are we failing the silent pandemic?"

Journal: Journal of internal medicine

Published: May 21, 2026

Derivation and Validation of Risk Prediction Models for Cardiovascular and Kidney Outcomes of Non-ST-Segment-Elevation Acute Coronary Syndrome in Patients With Chronic Kidney Disease.

Journal: Journal of the American Heart Association

Published: April 07, 2026

Atrasentan in patients with IgA nephropathy (ALIGN): final 2·5-year results from a randomised, double-blind, placebo-controlled, phase 3 trial.

Journal: Lancet (London, England)

Published: April 07, 2026

Efficacy and safety of canagliflozin are consistent across polypharmacy burden in CKD: the CREDENCE trial.

Efficacy and safety of canagliflozin are consistent across polypharmacy burden in CKD: the CREDENCE trial.

Does Intravenous Iron Improve Survival and Physical Function and Reduce Heart Failure Events in Patients with Chronic Kidney Disease?

Does Intravenous Iron Improve Survival and Physical Function and Reduce Heart Failure Events in Patients with Chronic Kidney Disease?

Reframing kidney outcomes in CKD trials: eGFR slopes, competing risks, and pragmatic trial design.

Reframing kidney outcomes in CKD trials: eGFR slopes, competing risks, and pragmatic trial design.

Design and baseline characteristics of the ZENITH high proteinuria trial testing zibotentan/dapagliflozin efficacy in CKD.

Design and baseline characteristics of the ZENITH high proteinuria trial testing zibotentan/dapagliflozin efficacy in CKD.

CV risk: if you aren't testing ACR, you aren't seeing the full picture.

CV risk: if you aren't testing ACR, you aren't seeing the full picture.

From Dialysis Expansion to Prevention-First Kidney Care: Lessons from Thailand's Response to CKD.

From Dialysis Expansion to Prevention-First Kidney Care: Lessons from Thailand's Response to CKD.

Sex disparities in receiving evidence-based medications in patients with CKD.

Sex disparities in receiving evidence-based medications in patients with CKD.

Authors reply: "Global kidney health: Are we failing the silent pandemic?"

Authors reply: "Global kidney health: Are we failing the silent pandemic?"

Derivation and Validation of Risk Prediction Models for Cardiovascular and Kidney Outcomes of Non-ST-Segment-Elevation Acute Coronary Syndrome in Patients With Chronic Kidney Disease.

Derivation and Validation of Risk Prediction Models for Cardiovascular and Kidney Outcomes of Non-ST-Segment-Elevation Acute Coronary Syndrome in Patients With Chronic Kidney Disease.

Atrasentan in patients with IgA nephropathy (ALIGN): final 2·5-year results from a randomised, double-blind, placebo-controlled, phase 3 trial.

Atrasentan in patients with IgA nephropathy (ALIGN): final 2·5-year results from a randomised, double-blind, placebo-controlled, phase 3 trial.

Global kidney health: Are we failing the silent pandemic?

Global kidney health: Are we failing the silent pandemic?

ISN International Expert Forum: Exploring the Nexus of Cardiovascular-Kidney-Metabolic (CKM) Health.

ISN International Expert Forum: Exploring the Nexus of Cardiovascular-Kidney-Metabolic (CKM) Health.